Should PIK3CA Inform Therapy Choice in Breast Cancer?Should PIK3CA Inform Therapy Choice in Breast Cancer?

Dr Lidia Schapira reports on a study showing that PIK3CA mutations may indicate trastuzumab resistance in HER2+ breast cancer but cautions use of the biomarker as a basis for clinical decisions. Medscape Oncology

Source: Medscape Hematology-Oncology Headlines - October 29, 2014 Category: Cancer & Oncology Tags: Hematology-Oncology Viewpoint Source Type: news